Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Histologically or cytologically confirmed carcinoma of the colon and/or rectum with
evidence of metastases

- At least one measurable metastatic lesion (as per RECIST criteria)

- Life expectancy of > 12 weeks

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Adequate hematological, renal and liver function

Exclusion Criteria:

- Prior chemotherapy for metastatic disease

- Clinically significant cardiovascular disease

- Ongoing treatment with aspirin (325 mg/day) or other medications known to predispose
for gastrointestinal ulceration

- Participation in an investigational trial in the previous 3 months

- Pregnant or lactating women

- History of thrombotic or haemorrhagic disorders

- Evidence of bleeding diathesis or coagulopathy

- Uncontrolled hypertension

- Known hypersensitivity to Avastin and any of its excipients, or any of the
chemotherapies

- Evidence of any disease or disorder that contraindicates the use of an
investigational drug or puts the patient at high risk for treatment-related
complications